---
title: "百時美施貴寶的股價已經連續七個交易日下跌"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/285992594.md"
description: "百時美施貴寶（BMY）股票連續七個交易日下跌，週一下跌 0.9%，報 55.64 美元。該股在之前六個交易日中下跌了 3.5%，過去一個月下跌了 5%，儘管年初至今上漲了 4%。該公司最近公佈的第一季度業績好於預期"
datetime: "2026-05-11T20:31:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285992594.md)
  - [en](https://longbridge.com/en/news/285992594.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285992594.md)
---

# 百時美施貴寶的股價已經連續七個交易日下跌

Bristol-Myers Squibb (BMY) shares fell for seven straight sessions, as the stock was down 0.9% at $55.64 on Monday. The New Jersey-based pharma giant fell 3.5% in the preceding six sessions. The stock is down 5% over the past one month, while it has advanced 4% so far this year. Most recently, Bristol-Myers Squibb reported better-than-expected Q1 2...

### 相關股票

- [BMY.US](https://longbridge.com/zh-HK/quote/BMY.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [PILL.US](https://longbridge.com/zh-HK/quote/PILL.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [RXL.US](https://longbridge.com/zh-HK/quote/RXL.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [CELG.RT.US](https://longbridge.com/zh-HK/quote/CELG.RT.US.md)

## 相關資訊與研究

- [巨生醫獲 SelectUSA 醫療科技組金牌 啟動美國 A 輪募資目標 1000 萬美元](https://longbridge.com/zh-HK/news/286905054.md)
- [川普投資組合神操作？Medicare 政策翻盤前 精準大買聯合健康](https://longbridge.com/zh-HK/news/287039034.md)
- [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)
- [鉅亨速報 - Factset 最新調查：Roivant Sciences LtdROIV-US 的目標價調升至 38 元，幅度約 8.57%](https://longbridge.com/zh-HK/news/287126179.md)
- [製藥巨頭集體擁抱 AI 智能體：百時美施貴寶向 3 萬員工推廣 Claude](https://longbridge.com/zh-HK/news/287074661.md)